Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Chronic heart failure

    - PMLiVE

    David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

    Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    Bayer symbol

    Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

    The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

    - PMLiVE

    FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

    The progressive neurodegenerative disease affects more than ten million people worldwide

    Bayer symbol

    Bayer UK launches digital educational hub to improve menopause support

    An estimated 13 million women in the UK are currently perimenopausal or menopausal

    Bayer symbol

    Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

    Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

    - PMLiVE

    MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

    Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

    Bayer symbol

    Bayer presents positive results for Kerendia in late-stage heart failure study

    Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

    Bayer symbol

    Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

    The companies will advance small molecule therapeutics against a new class of targets for cancer

    Bayer symbol

    Bayer shares promising results for Kerendia in phase 3 heart failure study

    Approximately 55% of heart failure patients have an LVEF of at least 40%

    - PMLiVE

    Merck and Daiichi Sankyo to jointly develop T-cell engager in deal worth over $170m

    The partners will evaluate MK-6070 as part of a combination treatment for small cell lung cancer

    - PMLiVE

    Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

    More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links